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 Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not anti-PD-
1/PD-L1 monoclonal antibodies are effective in prolonging overall survival in patients with 
advanced non-small cell lung cancer (NSCLC). 
 
Study Design: A systematic review and data analysis of three randomized control trials (RCTs) 
published after 2010. The studies were located in English written peer reviewed journals. 
 
Data sources: Three RCTs, which evaluated the efficacy of anti-PD-1/PD-L1 monoclonal 
antibodies, including nivolumab and pembrolizumab, as first and second or consecutive line 
therapy in patients with advanced NSCLC compared to cytotoxic agents. The studies utilized 
were found in EBSCO host and PubMed. 
 
Outcomes Measured: The primary endpoint of the studies was overall survival measured by 
quantifying survival rates at 6, 12, or 18 months.  
 
Results: All three RCTs (Borghaei 2015, Brahmer 2015, and Reck 2016) showed that anti PD-1 
monoclonal antibodies are effective in prolonging overall survival in patients with advanced 
NSCLC whose tumors expressed PD-L1 (p=.002, p<.001, and p=.005 respectively). All three 
studies proved that immunomodulating agents caused an increase in overall survival rates 
compared to those treated with chemotherapeutic agents as first and second or consecutive line 
therapy. Additionally, median overall survival time in months was significantly longer in patients 
who were treated with immunomodulating agents compared to cytotoxic agents. 
 
Conclusion: Based on the data analyzed from the studies represented throughout this systematic 
review, anti PD-1 monoclonal antibodies are effective in prolonging overall survival in patients 
with advanced NSCLC. It is unclear whether or not anti PD-L1 monoclonal antibodies are 
effective in prolonging overall survival in the same populations of NSCLC patients due to a lack 
of viable study selection found during the search process. All study conclusions were based on 
malignancies which expressed PD-L1 in their tumors. 
 
Keywords: NSCLC; PD1/PD-L1 Monoclonal Antibodies; Nivolumab; Pembrolizumab. 
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Introduction 
Lung cancer is a devastating disease that often doesn’t present itself until its later stages. 
Once symptomatic, a patient may present with constitutional manifestations such as fever, night 
sweats, fatigue, and weight loss. Symptoms related to the local invasion of the cancer include 
cough, hemoptysis, shortness of breath, back pain, and chest pain. A diagnosis of lung cancer can 
be made when pathology confirms malignancy of tumors originating in the lung or bronchus. 
The disease can then be further broken down into non-small cell and small cell, or NSCLC and 
SCLC respectively. NSCLC is much more common, accounting for approximately 80% of all 
lung cancer cases and comprises adenocarcinoma, squamous cell carcinoma, large cell 
carcinoma, and other less common malignant subtypes.1 Of the individuals who are diagnosed 
with NSCLC, over 50% are diagnosed with advanced disease, which generally includes stage 
IIIb and IV.1 This paper evaluates three randomized control trials (RCT’s) comparing the 
effectiveness of anti-PD-1/PD-L1 monoclonal antibodies on prolonging overall survival in 
patients with advanced non-small cell lung cancer. 
As of 2018, lung cancer is the most common cancer diagnosed in males and the third 
most common cancer diagnosed in females.2 In addition to its prevalence, lung cancer is the most 
common cause of cancer related deaths in the United States.3 For NSCLC, these statistics are due 
to two very critical diagnostic tools. First, Patients with NSCLC are often asymptomatic until the 
disease has advanced to terminal stages.3 Second, there is a lack of standardized screenings for at 
risk populations.3 As a result, it is imperative for health care providers to recognize risk factors 
and educate the patient on the severity of lung cancer to help prevent and detect lung cancer 
during earlier stages.  
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Malignancies originating in the lung and bronchus are the third costliest cancers in the  
United States.1 In 2011, the total healthcare costs over one year for lung cancer diagnosis and 
treatment was estimated to be $125,849 per person.4 Although necessary, the increased cost of 
lung cancer is due in part to comprehensive treatment that requires a complete healthcare team to 
appropriately manage the patient’s physical, mental, and emotional health throughout the disease 
course. Specifically, It is estimated that there will be 2 inpatient hospital admissions, 9 
cumulative inpatient care days, and 70 outpatient care visits during a one year period in a patient 
with NSCLC.4 Additionally, lung cancer risk increases with an individual’s age and older 
individuals with NSCLC represent a particularly expensive sub group of the overall lung cancer 
population due to comorbidities, disease burden, and lower overall performance.5 The cost 
analyses documented for populations diagnosed with lung cancer demonstrate a significant 
burden for patients and families. 
Preventing lung cancer is the best way to minimize insurance and out-of-pocket costs due 
to disease treatment. Prevention begins with identifying the most important risk factors and 
modifying the patient’s lifestyle to reduce the likelihood of cancer development. Smoking is the 
most important known risk factor for lung cancer and accounts for nearly 90% of all diagnoses.6 
Other risk factors for the development of NSCLC include poor diet, genetic susceptibility, and 
occupational exposures such as asbestos.6 When risk factors are present, it is uncertain if 
screening should be implemented. The current screening offered as a USPSTF Grade B is an 
annual low dose CT scan for adults 55-80 years old who have a 30 year or more pack-year 
history, but there is controversy surrounding when it should be offered.7 As an example, it is 
uncertain if higher risk populations, such as those with chronic bronchitis and emphysema, 
should be screened earlier or at more frequent intervals.7  
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Individuals who are diagnosed with NSCLC will endure varying degrees of treatment  
based on the staging and subtype of their cancer. In general, surgical removal of tumor(s) with or 
without regional lymph node resection is considered first line in patients with stage I-IIIa 
NSCLC.8 Cancers with more advanced disease, such as in stage IIIb-IV, indicate chemotherapy 
as first line therapy. For advanced NSCLC with no known tumor-specific mutations, 
administration of platinum based chemotherapy “doublets” such as cisplatin and carboplatin is 
warranted.8 Conversely, advanced NSCLC patients whose tumors express EGFR mutations are 
advised to begin treatment with EGFR-TKI’s.9  
Second line treatment for advanced NSCLC is limited and is dependent on the patient’s 
disease progression after first line treatment fails.10 Docetaxel is the current recommended 
second line treatment method, but has not been able to prove superiority to other current second 
line therapies.10 Programmed death 1/L1 (PD-1/PD-L1) receptors are immunomodulating agents 
that may offer superiority to the current first and second or third line treatment by prolonging 
survival in advanced NSCLC patients whose tumors express PD-1/PD-L1. The benefit in these 
medications is having more personalized treatment for diseases that involve the programmed cell 
death 1/L1 pathway. The purpose of the medications are to bind PD-1/PD-L1 receptors on B and 
T cells in the body and form an antibody complex.11 This prevents any tumor cells that express 
PD-1/PD-L1 from binding at those same sites on B and T cells. Without tumor cell binding on B 
and T cells, the immune system will be able to “restore antitumor immunity”.10 PD-1/PD-L1 
monoclonal antibodies such as nivolumab and pembrolizumab, may be more effective at 
prolonging overall survival than the current cytotoxic therapies recommended for first and 
second or consecutive line treatment. 
Objective 
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The objective of this selective EBM review is to determine whether or not anti PD-1/PD- 
L1 monoclonal antibodies are effective in prolonging overall survival in patients with advanced 
non-small cell lung cancer (NSCLC). 
Methods 
 This systematic review evaluates three randomized control trials (RCTs), which were 
selected after meeting specific criteria. The population of the review included men and women 
18 years or older with a confirmed diagnosis of advanced NSCLC and whose tumors expressed 
PD-1/PD-L1. “Advanced NSCLC” can be defined as stages IIIb or IV. The interventions 
included treatment with anti PD-1/PD-L1 monoclonal antibodies such as nivolumab and 
pembrolizumab, in variable doses. There were two comparison groups allowed in the review. 
The first comparison was to patients who have NOT received any treatment for their metastatic 
disease and the second comparison was to patients who HAVE received prior treatment that has 
failed/stopped. The primary outcome measured was overall survival rate over time, which 
generally occurred at 6, 12, or 18 months. 
 The articles selected for this systematic review were obtained through EBSCO host and 
PubMed. They are English written, peer reviewed articles and were chosen based on their 
relevance to the research topic and whether or not the outcome was patient oriented.  Additional 
inclusion criteria for the selection of the studies were: studies published after 2010, tumors 
expressing programmed death ligand, and primary outcomes measured by overall survival rate. 
Patients under the age of 18 and patients diagnosed with SCLC were among exclusion criteria. 
Keywords used during the search of the articles included NSCLC, PD1/PD-L1 monoclonal 
antibodies, nivolumab and pembrolizumab. A statistical summary of data was reported as 
p-value, RBI, ABI, and NNT. Confidence intervals were also included to demonstrate the  
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accuracy of the results. Demographics and characteristics of individuals included in the study are 
reported below (see table 1). 
Table 1 - Demographics & Characteristics of Included Studies 
Study Type # of 
Pts 
Avg. 
Age in 
yrs 
Inclusion Criteria Exclusion Criteria W
/D 
Intervention 
Borghaei 
(2015) 
RCT 582 62 Patients with: stage IIIb, 
IV or recurrent Non-
Squamous NSCLC who 
received a previous dose 
of platinum-based 
doublet chemotherapy 
and either radiation or 
surgical tumor resection. 
Patients had to be over 
18 years old, have an 
ECOG score of 0 or 1, 
and have adequate organ 
function. 
Patients with: 
autoimmune 
disease, 
symptomatic 
interstitial lung 
disease, systemic 
immunosuppression, 
prior treatment with 
immune-stimulatory 
antitumor agents, 
and prior use of 
docetaxel. 
22 Use of 
Nivolumab at 
a dose of 3 
mg/kg every 
2 weeks      
Brahmer 
(2015) 
RCT 272 63 Patients with: stage IIIb, 
IV or recurrent 
Squamous NSCLC who 
received a previous dose 
of platinum-based 
doublet chemotherapy 
and either radiation or 
surgical tumor resection. 
Patients had to be over 
18 years old, and have an 
ECOG score of 0 or 1. 
Patients with: 
autoimmune 
disease, 
symptomatic 
interstitial lung 
disease, systemic 
immunosuppression, 
prior treatment with 
immune-stimulatory 
antitumor agents, 
and prior use of 
docetaxel. 
12 Use of 
Nivolumab at 
a dose of 3 
mg/kg every 
2 weeks      
 
Reck 
(2016) 
RCT 355 65 Patients with stage IV 
NSCLC who were at 
least 18 years old, had no 
known ALK or EGFR 
mutations, and had an 
ECOG score of 0 or 1. 
Patients must not have 
received any prior 
systemic therapy for 
metastatic disease.  
Patients receiving 
immunosuppressive 
treatment such as 
glucocorticoids, 
with untreated brain 
metastatic lesions, 
active autoimmune 
disease, or history of 
interstitial lung 
disease. 
1 Use of 
Pembrolizu- 
mab given via 
IV at a dose 
of 200 mg 
every 3 
weeks for 35 
cycles  
 
Outcomes 
In the studies selected for this systematic review, the primary outcome was overall 
survival of advanced NSCLC patients treated with PD-1/PD-L1 monoclonal antibodies as a first 
and second or consecutive line therapy. Borghaei et al. and Brahmer et al. measured outcomes by 
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assessing median overall survival time in months, 1 year overall survival rate, 18 month overall 
survival rate, and death hazard ratio10,12 Reck et al. measured outcomes by assessing median 
overall survival time in months, overall survival rate at 6 months, and hazard death rate.13  
Overall survival was estimated via the Kaplan-Meier method. Response rate and progression free 
survival were measured as secondary endpoints, but are not being evaluated as they are outside 
of the scope of this systematic review. Symptomatic scales such as the Lung Cancer Symptom 
Scale and the European Quality of Life-5 Dimension Questionnaire were evaluated as part of 
progression free survival and will not be included in this review. 
Results 
 In a study conducted by Borghaei et al., 582 patients with advanced non-squamous 
NSCLC who were previously treated with a platinum-based doublet chemotherapy regimen were 
randomized to receive nivolumab or docetaxel.10 292 of the 582 patients received nivolumab 
while 290 of the 582 patients received docetaxel. No crossover was indicated for patients to 
switch from docetaxel to nivolumab or vice versa.  
 The median overall survival in patients who received nivolumab as a second line therapy 
was 12.2 months (95% confidence interval (CI), 9.7 to 15.0), and the median overall survival in 
patients who received docetaxel as a second line therapy was 9.4 months (95% CI, 8.1 to 10.7).10 
The 1 year overall survival rate was 51% (95% CI, 45 to 56) for individuals who received 
nivolumab and 39% (95% CI, 33 to 45) for individuals who received docetaxel.10 An additional 
follow-up conducted at 18 months showed that overall survival rates declined to 39% (95% CI, 
34 to 45) in the nivolumab group versus 23% (95% CI, 19 to 28) in the docetaxel group.10 The 
hazard ratio for death was calculated to be .73 (96% CI, 0.59 to 0.89, p=.002).10 Utilizing data 
from the 1 year survival rate, the numbers needed to treat (NNT) was 9 (see Table 2). This 
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indicates that for every 9 people treated with nivolumab, 1 person will live longer than if they 
had taken docetaxel. Overall, patients with advanced non-squamous NSCLC who received 
nivolumab as a second or consecutive line therapy lived significantly longer compared to those 
treated with docetaxel.  
Table 2 – Efficacy of nivolumab as a second line therapy in prolonging overall survival in 
patients with advanced NSCLC, measured by Borghaei 2015 
Study Relative Benefit 
Increase (RBI) 
Absolute Benefit 
Increase (ABI) 
Numbers 
Needed to 
Treat (NNT) 
Death Hazard 
Ratio P-Value 
Death Hazard 
Ratio Confidence 
Interval (CI) 
Borghaei 
(2015) 
.307 .120 9 .002 96% CI, 
.59-.89 
 
In a similar study conducted by Brahmer et al., 272 patients with advanced squamous 
non-small cell lung cancer who were previously treated with a regimen containing platinum-
based chemotherapy were randomized to receive nivolumab or docetaxel.12 137 of the 272 
patients received nivolumab while 137 of the 272 patients received docetaxel. No crossover was 
indicated during the study. 
 The median overall survival in patients who received nivolumab as a second line therapy 
was 9.2 months (95% CI, 7.3 to13.3), and the median overall survival in patients who received 
docetaxel as a second line therapy was 6.0 months (95% CI, 5.1 to 7.3).12 The 1 year overall 
survival rate was 42% (95% CI, 34 to 50) for individuals who received nivolumab and 24% 
((95% CI, 17 to 31) for individuals who received docetaxel.12 The hazard ratio for death was 
calculated to be .59 (95% CI, 0.44 to 0.79, P<0.001).12 Utilizing data from the 1 year survival 
rate, the numbers needed to treat (NNT) was 6 (see Table 3). This indicates that for every 6 
people treated with nivolumab, 1 person will live longer than if they had taken docetaxel. 
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Therefore, patients with advanced squamous NSCLC who received nivolumab lived significantly 
longer compared to those treated with docetaxel.  
Table 3 – Efficacy of nivolumab as a second line therapy in prolonging overall survival in 
patients with advanced NSCLC, measured by Brahmer 2015 
Study Relative Benefit 
Increase (RBI) 
Absolute Benefit 
Increase (ABI) 
Numbers 
Needed to 
Treat (NNT) 
Death Hazard 
Ratio P-Value 
Death Hazard 
Ratio Confidence 
Interval (CI) 
Brahmer 
(2015) 
.750 .180 6 <.001 95% CI, 
.44-.79 
 
Lastly, a study by Reck et al. was conducted to test the efficacy of pembrolizumab 
against advanced NSCLC. The study included 305 patients who had not been previously treated 
with any form of chemotherapy or radiation. 154 patients were treated with pembrolizumab and 
151 patient were treated with chemotherapy.13 The most common chemotherapeutic combination 
was carboplatin and pemetrexed, which was given to 67 out of the 151 patients. Crossover was 
allowed during this study if disease had progressed beyond an acceptable margin.13 In total, 66 
people in the chemotherapy group crossed over to the pembrolizumab group.  
 The 6 month overall survival rate in patients who received pembrolizumab as a first line 
therapy was 80.2% (95% CI, 72.9 to 85.7) and the 6 month overall survival rate in patients who 
received chemotherapy as a first line therapy was 72.4% (95% CI, 64.5 to 78.9).13 The hazard 
ratio for death was calculated to be .60 (95% CI, 0.41 to 0.89; P= 0.005).13 Utilizing data from 
the 1 year survival rate, the numbers needed to treat (NNT) was 13 (see Table 4). This indicates 
that for every 13 people treated with pembrolizumab, 1 person will live longer than if they had 
taken chemotherapy. Therefore, patients with advanced NSCLC who received pembrolizumab as 
first line therapy lived significantly longer compared to those treated with chemotherapy alone.  
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Table 4 – Efficacy of pembrolizumab as first line therapy in prolonging overall survival in 
patients with advanced NSCLC, measured by Reck 2016 
Study Relative Benefit 
Increase (RBI) 
Absolute Benefit 
Increase (ABI) 
Numbers 
Needed to 
Treat (NNT) 
Death Hazard 
Ratio P-Value 
Death Hazard 
Ratio Confidence 
Interval (CI) 
Reck 
(2016) 
.108 .078 13 .005 95% CI, 
.41-.89 
 
Discussion 
 Advanced non-small cell lung cancer is a terminal illness that typically weighs heavily on 
a patient in all aspects of their lives. Treatment options often exclude surgical tumor resection 
and focus solely on systemic cytotoxic agents that have limited efficacy. With advances in 
funding and research, metastatic lung neoplasia may be treated by modifying the immune 
response to the disease. The goal of this systematic review was to assess the efficacy of anti PD-
1/PD-L1 monoclonal antibodies in multiple stages of a patient’s treatment regimen, including as 
first and second line therapies. While the data collected points towards immunomodulators being 
effective in prolonging overall survival, several limitations and safety concerns have been 
identified relating to the context of this paper. 
 As the two medications studied for effectiveness, nivolumab and pembrolizumab were 
relatively safe medications offered compared to the current chemotherapeutic treatment options 
available for advanced NSCLC. Borghaei et al. and Brahmer et al. both identified that there were 
fewer adverse reactions with nivolumab compared to the chemotherapeutic agent, docetaxel.10,12 
Both studies evaluating nivolumab also reported similar adverse effects. Borghaei et al. 
documented that 16% of patients reported fatigue, 12% reported nausea, 10% reported decreased 
appetite, and 10% reported asthenia with nivolumab.10 Less common adverse events included 
rash, pruritis, erythema, diarrhea, hypothyroidism, increased liver function tests, and 
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pneumonitis.10 Brahmer et al. identified similar frequent side effects of nivolumab, including 
16% of patients reported fatigue, 11% reported decreased appetite, and 10% reported asthenia.12 
The safety profile of pembrolizumab was comparative to nivolumab, and showed that the most 
frequent adverse effects were immune-mediated responses to the medication.13 
 One important aspect relating to the use of monoclonal antibodies in treatment for 
advanced NSCLC is at what point the medications should be started. Through topic research, it 
was very clear that anti PD-1/PD-L1 monoclonal antibodies were studied as consecutive-line 
therapy in greater lengths. While Reck et al. focused on pembrolizumab as a first line agent for 
lung metastasis, both of the nivolumab studies conducted by Borghaei et al. and Brahmer et al. 
focused on therapy following a platinum-based doublet chemotherapy regimen.10,12,13 Efficacy 
was proven in all studies, but more research should be conducted to evaluate patient survival at 
several intervals following diagnosis, with and without prior and/or concurrent therapy. 
 A major limitation identified in the research of this evidence based medicine topic was 
the lack of available studies showing the efficacy specifically for PD-L1 monoclonal antibodies. 
Nivolumab and pembrolizumab are specifically known as PD-1 monoclonal antibodies, and 
these two medications were the only immunomodulators evaluated in this paper. Three PD-L1 
monoclonal antibodies that have been approved as immunomodulating agents, including 
atezolizumab, avelumab, and durvalumab. These medications have not been evaluated in this 
paper due to the lack of articles found during the selective search process. Nivolumab and 
pembrolizumab have been FDA approved since 2014, allowing more time for research to be 
conducted on their efficacy.10,12 Atezolizumab, avelumab, and durvalumab were approved in 
2016, 2017, and 2017 respectively and thus have less research available on their efficacy. 
Additionally, avelumab has not been approved yet for the treatment of advanced NSCLC.14 With 
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more funding and time, a greater number of RCT’s, cohort studies, and other analyses will be 
conducted across the entire PD-1/PD-L1 spectrum. With more studies available, a more 
comprehensive answer to the EBM question can be established. 
Conclusion 
 Anti PD-1 monoclonal antibodies are effective in prolonging overall survival in patients 
with advanced NSCLC. Unfortunately, it is unclear whether or not anti PD-L1 monoclonal 
antibodies have similar efficacy because there was very limited research evaluating medications 
that fall within its class. Nivolumab and pembrolizumab, which are anti PD-1 monoclonal 
antibodies, can be implemented in patients whose tumors express PD-L1 as first or consecutive 
line therapy as they are generally considered safer and more effective to the current 
recommended therapy. Atezolizumab, avelumab, and durvalumab should be evaluated under 
similar parameters to the studies discussed in this paper to understand their efficacy in 
prolonging overall survival in patients with NSCLC. 
 When the primary outcome of a study is prolonging or increasing overall survival, any 
increase from the current therapy available should be evaluated further and offered to patients 
with diseases who may benefit. In the upcoming years, it is expected that immunomodulating 
agents will make a greater impact in treating lung metastasis due to the promising results already 
seen. In a future study design, it would be adventitious to include all medications under the 
programmed death pathway and compare efficacy as first and second or consecutive line therapy. 
Additionally, inclusion of more study types, such as a cohort or prospective/retrospective 
analyses should be included. This information could determine which medication out of the drug 
class may offer the highest superiority in treating patients with advanced NSCLC whose tumors 
express PD-L1
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